Vanda Pharmaceuticals (VNDA) EBITDA (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted EBITDA of -$50.2 million for Q1 2026, down 24.46% sequentially from -$40.4 million in Q4 2025, and down 22.41% YoY from -$64.7 million in Q1 2025.
Vanda Pharmaceuticals (VNDA) EBITDA (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported EBITDA for 17 years, with the latest figure at -$50.2 million in Q1 2026.
- Quarterly EBITDA fell 22.41% year-over-year to -$50.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$160.4 million (down 121.34% YoY) and the FY2025 annual result came in at -$151.2 million, down 271.79% from the prior year.
- EBITDA fell to -$50.2 million in Q1 2026 per VNDA's latest filing, from -$40.4 million in the prior quarter.
- Over five years, EBITDA peaked at $6.6 million in Q4 2022 and troughed at -$50.2 million in Q1 2026.
- A 5-year average of -$14.7 million and a median of -$9.2 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2024: EBITDA soared 126.13% in 2023, then tumbled 560.83% in 2024.
- Over 5 years, EBITDA stood at $6.6 million in 2022, then tumbled by 207.01% to -$7.1 million in 2023, then plunged by 44.9% to -$10.3 million in 2024, then plunged by 292.58% to -$40.4 million in 2025, then dropped by 24.46% to -$50.2 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$50.2 million, -$40.4 million, and -$31.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | -63.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -63.81 Mn |
| Mar 31, 2026 | -50.22 Mn |
| Dec 31, 2025 | -40.35 Mn |
| Sep 30, 2025 | -31.28 Mn |
| Jun 30, 2025 | -38.50 Mn |
| Mar 31, 2025 | -41.03 Mn |
| Dec 31, 2024 | -10.28 Mn |
| Sep 30, 2024 | -11.00 Mn |
| Jun 30, 2024 | -10.15 Mn |
| Mar 31, 2024 | -9.24 Mn |
| Dec 31, 2023 | -7.09 Mn |
| Sep 30, 2023 | -6.00 Mn |
| Jun 30, 2023 | -2.87 Mn |
| Mar 31, 2023 | 2.00 Mn |
| Dec 31, 2022 | 6.63 Mn |
| Sep 30, 2022 | 3.91 Mn |
| Jun 30, 2022 | 3.46 Mn |
| Mar 31, 2022 | -7.67 Mn |
| Dec 31, 2021 | 8.64 Mn |
| Sep 30, 2021 | 10.82 Mn |